- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01650883
A Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients
A Randomized Prospective Open-label Comparison of Two Vitamin D3 Repletion Strategies in Vitamin D Deficient Patients
The purpose of this study is to determine whether one of two Vitamin D3 (cholecalciferol) oral treatment regimens is superior to the other in normalizing Vitamin 25 OHD serum levels. While these two regimens in the end provide equal total dosing, the two arms differ in frequency and dosing during a 40 day treatment plan. The primary endpoint will be a direct comparison of two dosing regimens of Vitamin D3 repletion at day 40 (+/- 3 days) using a paired T-test. Secondary endpoints include record of adverse events throughout the 40 day study period as well as changes in basic laboratory values including CMP and ionized Calcium.
The investigators hypothesize that the Cholecalciferol (Vitamin D3) daily dosing arm of 5000 IU daily will result in more efficient replacement as compared to the 50,000 IU dosing given every 10 days. Our goal will be to achieve a serum Vitamin 25 OH D level of > 50 mg/dL at day 40. The investigators propose that 75% of the subjects on daily Vitamin D3 will achieve this level and that 35% of the subjects in the every 10 days dosing arm will reach this goal.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
This is a 40 day randomized prospective open-label study of two arms of vitamin D repletion protocols. USF clinic patients seen in the Rheumatology clinic, who meet criteria and have a baseline vitamin 25 OH D level of less than or equal to 32 mg/dL, will be randomized to two treatment arms. A Vitamin 25 OH D level of less than 32 mg/dL but above 20 mg/dL will be defined as insufficient. Similarly, a vitamin 25 OH D level of less than or equal to 20 mg/dL will be defined as deficient.
Patients in arm one will be repleted with Cholecalciferol (Vitamin D3) at 5000 IU orally daily for 40 days. Arm two of this treatment protocol will consist of 50,000 IU cholecalciferol (Vitamin D3) orally every 10 days starting on day 1 for 40 days. All subjects in both groups will receive a total dose of 200,000 IU of Vitamin D3 after 40 days of treatment. Each patient will also receive oral supplementation of 1200 mg daily calcium carbonate. Patients will return to clinic on day 40 (+/- 3 days) for a follow up serum vitamin 25 OH D and Calcium level. Compliance will be checked at that time with a pill count.
Clinical Significance: This trial asks the question as to whether one oral repletion therapy is superior to another in a 40 day time period. Given that current standard of care is based on individual practitioner experience, it may be beneficial for a standard protocol.
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Florida
-
Tampa, Florida, United States, 33612
- University of South Florida
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Age 18 - open ended to both males and females
- Able to give informed consent
- 25 OH-Vitamin D level of < or = 32 mg/dL
- Creatinine of < 1.9 or Creatinine Clearance (CrCl) of greater than or equal to 40 mL/min/1.73 m^2.
- English speaking
Exclusion Criteria:
- Creatinine of greater to or equal to 1.9 or CrCl less than 40 mL/min/1.73 m^2 (as calculated on MDRD.com)
- History of hyperparathyroidism, a known risk factor for hyperkalemia
- History of nephrolithiasis given that hypervitaminosis D can increase the risk of nephrolithiasis
- Current use of any dose of glucocorticoids, a known risk factor for hypercalcuria
- History of sarcoidosis, tuberculosis, or Paget's disease which are known risk factors for hypercalcemia
- (Random) Molar Calcium:Creatinine urinary concentration of > 1
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Cholecaliferol 50,000 IU PO Q10 days x 40 days
Patients in this arm receive Cholecalciferol (vitamin D3) via PO route every 10 days for 40 days for a total of 200,000 IU of Vitamin D3.
They also receive daily 1200 mg of Calcium Carbonate via PO route daily for 40 days.
|
Cholecalciferol 50,000 IU PO every 10 days for 40 days
Other Names:
|
Experimental: Cholecalciferol 5,000 IU PO daily x 40 days
Patients in this arm receive 5,000 IU of Cholecalciferol (Vitamin D3) via PO route daily for 40 days for a total of 200,000 IU.
These patients also receive 1200 mg of daily Calcium Carbonate via PO route for 40 days.
|
Cholecalciferol 5,000 IU PO daily for 40 days + 1200 mg Calcium Carbonate PO daily for 40 days.
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
The primary endpoint will be a direct comparison of two dosing regimens of Vitamin D3 repletion at day 40 (+/- 3 days) using a paired sample T-test by measuring the change in Vitamin D 25 OH from baseline to day 40 of treatment for both treatment groups.
Time Frame: 40 days +/- 3 days
|
40 days +/- 3 days
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse events throughout the 40 day study
Time Frame: 40 +/- 3 days
|
40 +/- 3 days
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Julio Gonzalez, MD, University of South Florida College of Medicine
- Principal Investigator: John D Carter, MD, University of South Florida Division of Rheumatology
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- VitD3USFstudy
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Vitamin D 25 OH Deficiency
-
Azienda Ospedaliera di BolzanoCompleted25(OH)D Measurement and 25(OH)D Deficiency
-
University of Eastern FinlandDSM Nutritional Products, Inc.CompletedVitamin D Receptor Target Gene Expression | Serum 25(OH)D ConcentrationFinland
-
University of Eastern FinlandCompletedVitamin D Receptor Target Gene Expression | Serum 25(OH)D ConcentrationFinland
-
King Faisal Specialist Hospital & Research CenterCompletedVitamin D Deficiency | 25-Hydroxyvitamin D ConcentrationSaudi Arabia
-
University of UlsterDairy Council for Northern Ireland; Agri-food & Biosciences Institute; Center...Completed
-
Instituto Nacional de Salud Publica, MexicoDSM Nutritional Products, Inc.CompletedVitamin D Deficiency | 25-Hydroxyvitamin D3 Deficiency, SelectiveMexico
-
University College CorkCompletedVitamin D Status as Reflected by Serum 25-hydroxyvitamin DIreland
-
Instituto Nacional de Salud Publica, MexicoDSM Nutritional Products, Inc.CompletedVitamin D Deficiency | 25-Hydroxyvitamin D3 Deficiency, SelectiveMexico
-
Federal University of Rio Grande do SulCompletedDeficiency, Vitamin DBrazil
-
University Hospital, Clermont-FerrandTerminated
Clinical Trials on Cholecalciferol
-
Medical University of South CarolinaTerminatedVitamin D Deficiency | Nutritional DeficiencyUnited States
-
Centre of Postgraduate Medical EducationUnknownInfant, Premature, DiseasesPoland
-
Johns Hopkins UniversityNational Institute on Aging (NIA)TerminatedVitamin D Deficiency | FallsUnited States
-
University of PittsburghNational Heart, Lung, and Blood Institute (NHLBI)CompletedCystic Fibrosis | Allergic Bronchopulmonary AspergillosisUnited States
-
Rashid Centre for Diabetes and ResearchCompletedObesity | Type 2 Diabetes Mellitus | Hypovitaminosis DUnited Arab Emirates
-
University Hospitals Cleveland Medical CenterUniversity of Colorado, DenverCompletedInflammationUnited States
-
University Hospital, AngersMylan LaboratoriesCompleted
-
Medical University of South CarolinaEunice Kennedy Shriver National Institute of Child Health and Human Development... and other collaboratorsCompleted
-
Assistance Publique - Hôpitaux de ParisLaboratoire CrinexCompletedRenal Transplant Candidate for Right KidneyFrance